MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Atara Biotherapeutics Company Profile (NASDAQ:ATRA)

Consensus Ratings for Atara Biotherapeutics (NASDAQ:ATRA) (?)
Ratings Breakdown: 1 Sell Rating(s), 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $29.50 (29.39% upside)

Analysts' Ratings History for Atara Biotherapeutics (NASDAQ:ATRA)
Show:
DateFirmActionRatingPrice TargetActions
6/7/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Jefferies GroupReiterated RatingBuy$22.00 -> $25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$40.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$40.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman Sachs Group Inc.Lower Price Target$30.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Citigroup Inc.Lower Price Target$16.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/15/2015William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for Atara Biotherapeutics (NASDAQ:ATRA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q1($0.55)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015($0.53)($0.43)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.44)($0.43)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015($0.35)($0.67)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q314($4.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Atara Biotherapeutics (NASDAQ:ATRA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.68)($0.68)($0.68)
Q2 20161($0.65)($0.65)($0.65)
Q3 20161($0.76)($0.76)($0.76)
Q4 20161($0.86)($0.86)($0.86)
Q1 20171($0.87)($0.87)($0.87)
Q2 20171($0.88)($0.88)($0.88)
Q3 20171($0.89)($0.89)($0.89)
Q4 20171($0.90)($0.90)($0.90)
(Data provided by Zacks Investment Research)
Dividend History for Atara Biotherapeutics (NASDAQ:ATRA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Atara Biotherapeutics (NASDAQ:ATRA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/24/2016Isaac E CiechanoverCEOSell9,600$21.26$204,096.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2016Isaac E CiechanoverCEOSell12,000$20.53$246,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2016Isaac E CiechanoverCEOSell7,200$20.36$146,592.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2016Isaac E CiechanoverCEOSell7,200$17.69$127,368.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2016Carol Giltner GallagherDirectorSell1,184$15.96$18,896.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2016Gad SofferCOOSell5,427$15.91$86,343.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016John McgrathCFOSell5,395$15.77$85,079.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Mitchall G ClarkInsiderSell4,153$15.15$62,917.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/26/2016Isaac E CiechanoverCEOSell1,300$20.12$26,156.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/12/2016Isaac E CiechanoverCEOSell13,210$20.40$269,484.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Isaac E CiechanoverCEOSell1,190$20.03$23,835.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Eric DobmeierDirectorBuy3,000$13.86$41,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Carol Giltner GallagherDirectorSell1,183$16.30$19,282.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Gad SofferCOOSell5,711$16.77$95,773.47View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2016Isaac E CiechanoverCEOSell2,400$20.20$48,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/31/2015Isaac E CiechanoverCEOSell2,400$26.00$62,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015Eric DobmeierDirectorBuy2,500$22.00$55,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Isaac E CiechanoverCEOSell2,400$22.46$53,904.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2015Isaac E CiechanoverCEOSell4,000$37.45$149,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2015John McgrathCFOSell6,000$40.00$240,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Isaac E CiechanoverCEOSell4,800$35.03$168,144.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Carol Giltner GallagherDirectorSell1,184$31.10$36,822.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Gad SofferCOOSell7,586$31.22$236,834.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2015Isaac E CiechanoverCEOSell3,200$25.85$82,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015Isaac E CiechanoverCEOSell4,000$33.08$132,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2015Isaac E CiechanoverCEOSell5,200$42.99$223,548.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2015Isaac E. CiechanoverCEOSell5,200$46.16$240,032.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Christopher HaqqinsiderSell5,000$41.99$209,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Isaac E CiechanoverCEOSell5,200$39.25$204,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/24/2015Carol Giltner GallagherDirectorSell17,622$42.34$746,115.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015Carol Giltner GallagherDirectorSell5,875$48.18$283,057.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Carol Giltner GallagherDirectorSell5,764$49.38$284,626.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Gad SofferCOOSell7,711$49.49$381,617.39View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015John McgrathCFOSell6,000$49.38$296,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Gad SofferCOOSell8,778$50.00$438,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Mitchall G ClarkInsiderSell7,829$46.19$361,621.51View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Isaac E CiechanoverCEOSell5,200$60.71$315,692.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Christopher HaqqInsiderSell2,500$62.94$157,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Christopher HaqqInsiderSell2,500$51.68$129,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Isaac E CiechanoverCEOSell5,200$50.42$262,184.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Isaac E CiechanoverCEOSell5,200$54.72$284,544.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Christopher HaqqInsiderSell7,500$46.42$348,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015John McgrathCFOSell10,000$50.00$500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Isaac E CiechanoverCEOSell6,400$42.91$274,624.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Christopher HaqqInsiderSell2,500$41.47$103,675.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2015John McgrathCFOSell10,000$40.00$400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2015Isaac E CiechanoverCEOSell4,000$37.56$150,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/23/2015Isaac E CiechanoverCEOSell5,200$61.36$319,072.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Joel S MarcusDirectorBuy4,000$29.57$118,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2015Carol Giltner GallagherDirectorBuy11,000$18.00$198,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2014Domain Partners Viii, L.P.Major ShareholderBuy248,159$11.00$2,729,749.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Atara Biotherapeutics (NASDAQ:ATRA)
DateHeadline
06/29/16 02:37 PMAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Current Analyst Ratings - Fiscal Standard
06/28/16 02:52 PMAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Earnings Glance and Target Price Review - Engelwood Daily
06/26/16 07:48 AMAtara Biotherapeutics Incorporated (NASDAQ:ATRA) Shorted Shares Increased 1.69% After Market Selling - Press Telegraph
06/25/16 02:38 PMWere Analysts Bullish Atara Biotherapeutics Inc (NASDAQ:ATRA) This Week? - Engelwood Daily
06/25/16 07:19 AMShare Volatility Check for: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Press Telegraph
06/24/16 03:32 PMATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/23/16 10:02 PMATARA Biotherapeutics (ATRA) Announces Medicinal Product Classification for Allogeneic EBV-CTLs from EMA
06/23/16 04:06 PMATARA Biotherapeutics (ATRA) Announces Medicinal Product Classification for Allogeneic EBV-CTLs from EMA - StreetInsider.com
06/23/16 08:49 AMAtara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from European Medicines Agency (EMA) - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 23, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe ...
06/22/16 07:48 PMWith incubator partnership, one of world's largest biotech cozies up to startups
06/22/16 07:26 AMStrong Buy Calls Count For Atara Biotherapeutics, Inc. (NASDAQ:ATRA) At 4 - Investor Newswire
06/19/16 02:36 PMAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Analyst Price Targets For The Coming Week - Fiscal Standard
06/16/16 02:40 PMAtara Biotherapeutics : Bio to Present at the JMP Securities Life Sciences Conference
06/16/16 07:01 AMAtara Biotherapeutics, Inc. (ATRA) - Financial and Strategic SWOT Analysis Review - New Market Study Published
06/15/16 03:19 PMAtara Bio to Present at the JMP Securities Life Sciences Conference - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 15, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe ...
06/13/16 02:54 PMStock Highlights: Atara Biotherapeutics, Inc. (NASDAQ:ATRA), Weatherford International plc (NYSE:WFT), Stein Mart ... - KC Register
06/08/16 08:58 PMATARA BIOTHERAPEUTICS INC. (NASDAQ:ATRA) Financial Condition Compared to S&P 500 - CML News
06/06/16 08:04 PMResults Presented at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
06/06/16 08:04 PMAtara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using
06/06/16 05:48 PMAtara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe ...
06/06/16 02:29 PMAtara Biotherapeutics, (NASDAQ:ATRA) Decreased -5.02%: Sibanye Gold (NYSE:SBGL), First Cash Financial Services ... - KC Register
06/05/16 10:31 AMAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Broker Price Targets For The Coming Week - Share Trading News
06/03/16 11:10 AMAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News
06/02/16 11:58 AMAtara Biotherapeutics, Inc. :ATRA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
05/31/16 03:13 PMAtara Bio to Present at Three Upcoming Investor Conferences - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe ...
05/30/16 10:52 PMStock Review and Earnings Check on Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - HNN - Stock Review and Earnings Check on Atara Biotherapeutics, Inc. (NASDAQ:ATRA)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Atara Biotherapeutics, Inc.and more »
05/30/16 10:52 PMStock Review and Earnings Check on Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - HNN - Stock Review and Earnings Check on Atara Biotherapeutics, Inc. (NASDAQ:ATRA)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Atara Biotherapeutics, Inc.and more »
05/18/16 07:02 PMUPDATE: New Abstract Links -- Atara Bio Announces Presentations of Clinical Data from EBV-CTL and STM 434 Product Candidates at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe ...
05/18/16 05:12 PMAtara Bio Announces Presentations of Clinical Data from EBV-CTL and STM 434 Product Candidates at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe ...
05/13/16 12:04 PMATARA BIOTHERAPEUTICS, INC. Financials -
05/09/16 07:28 AMAtara Bio's Collaborating Investigators to Present Clinical Data on EBV-CTL at 2016 American Transplant Congress - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe ...
05/09/16 07:00 AMAtara Bio’s Collaborating Investigators to Present Clinical Data on EBV-CTL at 2016 American Transplant Congress - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., May 09, 2016-- Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that ...
05/06/16 03:53 PMATARA BIOTHERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -
05/05/16 02:31 PMAtara Biotherapeutics reports 1Q loss -
05/05/16 10:08 AMATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a -
05/05/16 07:21 AMAtara Bio Announces First Quarter 2016 Financial Results and Recent Highlights - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe ...
04/19/16 04:22 PMAtara Bio's Collaborator QIMR Berghofer Medical Research Institute Reports Positive Clinical Data for T Cell Immunotherapy in Nasopharyngeal Cancer (NPC), a Solid Tumor - [at noodls] - Results Highlighted in Oral Presentation at the 2016 American Association for Cancer Research (AACR) Annual Meeting Atara Bio and QIMR Berghofer Collaborating to Develop Next Generation 'Off-the-Shelf' ...
04/19/16 04:15 PMAtara Bio’s Collaborator QIMR Berghofer Medical Research Institute Reports Positive Clinical Data for T Cell Immunotherapy in Nasopharyngeal Cancer (NPC), a Solid Tumor - [GlobeNewswire] - Results Highlighted in Oral Presentation at the 2016 American Association for Cancer Research Annual Meeting. Atara Bio and QIMR Berghofer Collaborating to Develop Next Generation "Off-the-Shelf" ...
02/26/16 11:49 AMEPS Preview for Atara Biotherapeutics Inc (ATRA) - OctaFinance.com - EPS Preview for Atara Biotherapeutics Inc (ATRA)OctaFinance.comAnalysts await Atara Biotherapeutics Inc (NASDAQ:ATRA) to reports earnings on February, 25. They expect $-0.56 EPS, up 16.42 % or $0.11 from last year's $-0.67 per share. After $-0.43 actual EPS reported by Atara Biotherapeutics Inc for the previous ...
02/16/16 05:14 AMATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
02/14/16 01:20 PMWhat Will Happen to Atara Biotherapeutics Inc Next? The Stock Just Reaches 52-Week Low - Sonoran Weekly Review - What Will Happen to Atara Biotherapeutics Inc Next? The Stock Just Reaches 52-Week LowSonoran Weekly ReviewThe stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) hit a new 52-week low and has $13.71 target or 11.00% below today's $15.41 share price. The 7 months bearish chart indicates high risk for the $416.25M company. The 1-year low was reported on Feb, ...
02/14/16 01:20 PMAtara Biotherapeutics Incorporated (NASDAQ:ATRA) Shorted Shares Decreased By 5.85% - fdanewsalert.com - Atara Biotherapeutics Incorporated (NASDAQ:ATRA) Shorted Shares Decreased By 5.85%fdanewsalert.comThe short interest to Atara Biotherapeutics Incorporated's float is 20.43%. The stock is up 7.35% or $1.03 after the news, hitting $15.04 per share. About 145,643 shares traded hands. Atara Biotherapeutics Inc (NASDAQ:ATRA) has declined 73.77% since ...Atara Biotherapeutics, Inc. (NASDAQ:ATRA) PT & Analyst Recommendation ReviewUptick AnalystWhat's in Atara Biotherapeutics Inc After Today's Huge Increase?Sonoran Weekly Reviewall 3 news articles »
02/08/16 01:57 PMATARA Biotherapeutics (ATRA) Granted FDA Orphan Drug Status for EBV-CTL - StreetInsider.com - ATARA Biotherapeutics (ATRA) Granted FDA Orphan Drug Status for EBV-CTLStreetInsider.comAtara Biotherapeutics, Inc. (Nasdaq: ATRA) announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for the Company's T-lymphocyte product candidate activated against Epstein-Barr Virus (EBV-CTL) for the treatment of ...Atara Bio Receives FDA Orphan Drug Designation for EBV-CTL to Treat Epstein-Barr Virus-Associated Post-Transplant ...PharmiWeb.com (press release)all 5 news articles »
02/08/16 01:57 PMATARA Biotherapeutics (ATRA) Granted FDA Orphan Drug Status for EBV-CTL - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for the Company’s T-lymphocyte ...
02/08/16 07:01 AM8:01 am Atara Biotherapeutics confirms FDA granted orphan drug designation for the Company's T-lymphocyte product candidate activated against Epstein-Barr Virus -
02/08/16 07:00 AMAtara Bio Receives FDA Orphan Drug Designation for EBV-CTL to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder (EBV-PTLD) - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Feb. 08, 2016-- Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that ...
02/07/16 01:01 PMAtara Biotherapeutics Incorporated (NASDAQ:ATRA) Short Interest Increased By 26.29% - fdanewsalert.com - Atara Biotherapeutics Incorporated (NASDAQ:ATRA) Short Interest Increased By 26.29%fdanewsalert.comThe short interest to Atara Biotherapeutics Incorporated's float is 21.7%. The stock decreased 8.92% or $1.68 during the last trading session, hitting $17.16. About 185,158 shares traded hands. Atara Biotherapeutics Inc (NASDAQ:ATRA) has declined 58.44 ...Buzzing Stock : Atara Biotherapeutics, Inc. (NASDAQ:ATRA)?Vanguard TribuneAtara Biotherapeutics, Inc. (NASDAQ:ATRA): Sell-side Look at EarningsUptick AnalystIt Seems Atara Biotherapeutics Inc Will Go Down. Have Another Big DeclineSonoran Weekly Reviewall 4 news articles »
02/04/16 01:28 PMTime to Buy Atara Biotherapeutics Inc After Reaching 52-Week Low? - WallStreet.org - Time to Buy Atara Biotherapeutics Inc After Reaching 52-Week Low?WallStreet.orgThe stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) hit a new 52-week low and has $16.97 target or 5.00% below today's $17.86 share price. The 5 months bearish chart indicates high risk for the $516.79M company. The 1-year low was reported on Feb, ...
02/04/16 12:40 PMNovo Nordisk Posts In Line Q4 Earnings, Tops Revenues -
02/03/16 12:58 PMNASDAQ:ATRA Stockholder Notice: Investigation over potential Securities Laws Violations by Atara Biotherapeutics Inc - Empowered News - NASDAQ:ATRA Stockholder Notice: Investigation over potential Securities Laws Violations by Atara Biotherapeutics IncEmpowered NewsOn December 14, 2015, Atara Biotherapeutics Inc (NASDAQ:ATRA) announced results from its Phase 2 proof-of-concept clinical trial for PINTA 745 for the treatment of protein energy wasting (PEW) in patients with end stage renal disease (ESRD).
About Atara Biotherapeutics

Atara Biotherapeutics logoAtara Biotherapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics for serious unmet medical needs with an initial focus on muscle wasting conditions and oncology. The Company's lead product candidate, PINTA 745 is a peptibody that binds myostatin and inhibits its corresponding signal transduction, thereby blocking the negative regulation of skeletal muscle growth. PINTA 745 is in a Phase II clinical trial. The Company's second product candidate, STM 434, which is in a Phase I clinical study, is a soluble ActR2B receptor that binds Activin A. The Company has five additional product candidates: ATA 842, a humanized antibody targeting myostatin; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-ActR2A/2B monoclonal antibody; STM 217, a soluble ActR2B receptor-IgG Fc fusion protein and a close analog of STM 434, and ActR2B5, a soluble ActR2B receptor that can be fused to an IgG Fc receptor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ATRA
  • CUSIP:
Key Metrics:
  • Previous Close: $22.51
  • 50 Day Moving Average: $19.18
  • 200 Day Moving Average: $19.10
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $649.33M
  • Current Quarter EPS Consensus Estimate: $-2.64 EPS
Additional Links:
Atara Biotherapeutics (NASDAQ:ATRA) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha